Astellas Pharma Inc. (OTCMKTS:ALPMY) Sees Large Growth in Short Interest

Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the target of a large growth in short interest in May. As of May 31st, there was short interest totalling 62,900 shares, a growth of 555.2% from the May 15th total of 9,600 shares. Based on an average daily trading volume, of 222,800 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.0% of the company's stock are sold short.

Astellas Pharma Stock Up 0.1%

Shares of ALPMY traded up $0.01 during midday trading on Thursday, reaching $9.76. 92,130 shares of the stock were exchanged, compared to its average volume of 197,936. Astellas Pharma has a 52 week low of $8.37 and a 52 week high of $13.14. The company's 50 day moving average is $9.55 and its two-hundred day moving average is $9.71. The company has a market capitalization of $17.66 billion, a P/E ratio of -44.36 and a beta of 0.23. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 0.39.

Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last announced its quarterly earnings results on Friday, April 25th. The company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.15 by $0.12. Astellas Pharma had a positive return on equity of 13.69% and a negative net margin of 3.10%. The business had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.02 billion. On average, sell-side analysts anticipate that Astellas Pharma will post 0.42 earnings per share for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.